Scientists unveil surprising human vs. mouse differences in a major cancer immunotherapy target
Since its discovery in the 1990s, programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer ...
C&EN2d
Flawed assumptions could be spoiling cancer immunotherapy research
Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to ...
Hosted on MSN4d
Study reveals major differences between human and mouse PD-1 in cancer research
Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments. A "checkpoint" receptor that often resides on the surface of ...
SMA12h
Raising SMN protein levels may be helpful early step in SMA treatment
Combining a premade SMN protein with a Spinraza-like drug (targets SMN2 gene) helped patient-derived motor neurons; potential ...
EurekAlert!2d
New research demonstrates how bad eggs are identified for destruction by the reproductive system
A novel molecular tool developed by a Lehigh University professor of biological sciences is enabling scientists to precisely ...
Breakthrough Discovery Reveals Hidden Flaws in Cancer Research Models
Scientists have discovered significant discrepancies in PD-1 between humans and rodents, indicating that common lab models ...
Phys.org19d
Introducing perceptein, a protein-based artificial neural network in living cells
Westlake University in China and the California Institute of Technology have designed a protein-based system ... to stay alive or undergo programmed cell death. Cells naturally process multiple ...
C&EN22d
A protein-based neural network for cells
In this case, the protein-based neural network allows the comparison of multiple inputs and provides a single output, such as programmed cell death or differentiation. A neural network ...
Medindia2d
Artificial Intelligence Transforming Glaucoma Drug Discovery
Artificial intelligence-enabled discovery of a RIPK3 inhibitor with neuroprotective effects in an acute glaucoma mouse model ...
Pharmaceutical Technology9d
GXP-1 by Egret Therapeutics for Transplant Rejection: Likelihood of Approval
GXP-1 is under clinical development by Egret Therapeutics and currently in Phase I for Transplant Rejection. According to GlobalData, Phase I drugs for Transplant Rejection have an 84% phase ...
Pharmaceutical Technology10d
Cadonilimab by Akeso for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Metastatic Renal Cell Carcinoma.
Business Wire12d
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today annou ...